Immunic (NASDAQ:IMUX) Releases Earnings Results, Beats Expectations By $0.36 EPS

Immunic (NASDAQ:IMUX) announced its quarterly earnings data on Tuesday. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.36, FiscalAI reports.

Immunic Price Performance

Immunic stock opened at $14.62 on Tuesday. Immunic has a fifty-two week low of $5.06 and a fifty-two week high of $15.84. The firm’s 50 day simple moving average is $14.29 and its 200-day simple moving average is $11.84. The company has a market cap of $199.12 million, a P/E ratio of -2.60 and a beta of 1.41.

Institutional Trading of Immunic

Large investors have recently added to or reduced their stakes in the company. Qube Research & Technologies Ltd acquired a new position in Immunic during the third quarter valued at $29,000. Two Sigma Investments LP acquired a new position in shares of Immunic in the 3rd quarter valued at about $52,000. Virtu Financial LLC purchased a new stake in shares of Immunic in the third quarter worth approximately $99,000. Jane Street Group LLC lifted its position in shares of Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock worth $226,000 after purchasing an additional 152,726 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Immunic during the fourth quarter worth approximately $120,000. 51.82% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on IMUX shares. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price (up from $5.00) on shares of Immunic in a report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a research note on Friday, May 29th. Wolfe Research initiated coverage on shares of Immunic in a research note on Friday, May 22nd. They issued an “outperform” rating on the stock. Stifel Nicolaus set a $25.00 target price on shares of Immunic and gave the company a “buy” rating in a research note on Thursday, April 16th. Finally, LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $47.57.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.